Press Release

Medac at the EADV 2017

Methotrexate for psoriasis: effective, safe, favourable.

Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva.

Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no wonder that recent treatment recommendations consider MTX as first-line and cost-effective therapeutic for the systemic treatment of psoriasis. And still the potential of MTX is often not fully exploited. In particular the dose and route of administration are aspects that should be considered.

Click here to view full Press release